BRÈVE

sur Psycheceutical, Inc. (NASDAQ:BWVI)

Psycheceutical Bioscience, Inc. Faced with Enduring Regulatory Challenges

MIAMI, FL—Psycheceutical Bioscience, Inc., a prominent bioscience company, has publicly addressed its continuous struggle with regulatory filing deficiencies which have been obstructing corporate actions like name and symbol changes, mergers and acquisitions, and reverse splits for over a decade. Despite these setbacks, which typically lead companies to insolvency and potential bankruptcy, Psycheceutical is actively seeking ways to prevent such outcomes.

Neilank K. Jha, MD, Executive Chairman & CEO of Psycheceutical, stated that the company is collaboratively working with various professionals to navigate these challenges. He also emphasized their commitment to maintaining transparency with shareholders and expects to share updates on their progress soon. Psycheceutical remains optimistic about its future plans enhancing shareholder value despite ongoing regulatory hurdles.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Psycheceutical, Inc.